de Vrij Nicky, Pollmann Julia, Rezende Antonio M, Ibarra-Meneses Ana V, Pham Thao-Thy, Hailemichael Wasihun, Kassa Mekibib, Bogale Tadfe, Melkamu Roma, Yeshanew Arega, Mohammed Rezika, Diro Ermias, Maes Ilse, Domagalska Malgorzata A, Landuyt Hanne, Vogt Florian, van Henten Saskia, Laukens Kris, Cuypers Bart, Meysman Pieter, Beyene Hailemariam, Sisay Kasaye, Kibret Aderajew, Mersha Dagnew, Ritmeijer Koert, van Griensven Johan, Adriaensen Wim
Clinical Immunology Unit, Department of Clinical Sciences, Institute of Tropical Medicine, 2000, Antwerp, Belgium.
Adrem Data Lab, Department of Computer Science, University of Antwerp, 2020, Antwerp, Belgium.
Commun Biol. 2024 May 3;7(1):524. doi: 10.1038/s42003-024-06225-2.
A large proportion of HIV-coinfected visceral leishmaniasis (VL-HIV) patients exhibit chronic disease with frequent VL recurrence. However, knowledge on immunological determinants underlying the disease course is scarce. We longitudinally profiled the circulatory cellular immunity of an Ethiopian HIV cohort that included VL developers. We show that chronic VL-HIV patients exhibit high and persistent levels of TIGIT and PD-1 on CD8/CD8 T cells, in addition to a lower frequency of IFN-γ TIGIT CD8/CD8 T cells, suggestive of impaired T cell functionality. At single T cell transcriptome and clonal resolution, the patients show CD4 T cell anergy, characterised by a lack of T cell activation and lymphoproliferative response. These findings suggest that PD-1 and TIGIT play a pivotal role in VL-HIV chronicity, and may be further explored for patient risk stratification. Our findings provide a strong rationale for adjunctive immunotherapy for the treatment of chronic VL-HIV patients to break the recurrent disease cycle.
很大一部分合并感染HIV的内脏利什曼病(VL-HIV)患者表现为慢性病,VL频繁复发。然而,关于该疾病病程背后的免疫决定因素的知识却很匮乏。我们对一个包括VL发病者的埃塞俄比亚HIV队列的循环细胞免疫进行了纵向分析。我们发现,慢性VL-HIV患者的CD8/CD8 T细胞上TIGIT和PD-1水平高且持续,此外,IFN-γ TIGIT CD8/CD8 T细胞频率较低,提示T细胞功能受损。在单个T细胞转录组和克隆分辨率水平上,患者表现出CD4 T细胞无反应性,其特征是缺乏T细胞活化和淋巴细胞增殖反应。这些发现表明,PD-1和TIGIT在VL-HIV慢性病中起关键作用,可能需要进一步探索用于患者风险分层。我们的发现为辅助免疫疗法治疗慢性VL-HIV患者以打破复发性疾病循环提供了有力依据。